Company / Operating Income
Akebia Therapeutics, Inc. Operating Income History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$23.5M
FY2025
5-year range
-$286.3M / $23.5M
FY2021-FY2025
Trend
+146.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$286M in FY2021 to $23M in FY2025.
Based on SEC 10-K filings.
$23M in FY2025.
Improved from -$46M to $23M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 146.6% year-over-year.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.5M | +146.6% |
| FY2024 | -$50.5M | -9.1% |
| FY2023 | -$46.3M | +42.7% |
| FY2022 | -$80.8M | +71.8% |
| FY2021 | -$286.3M | -60.7% |
| FY2020 | -$178.2M | -132.4% |
| FY2019 | -$76.7M | +43.8% |
| FY2018 | -$136.5M | -756.5% |
| FY2015 | -$15.9M | -86.9% |
| FY2014 | -$8.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026